P2X3 receptor involvement in endometriosis pain via ERK signaling pathway. [PDF]
PLoS ONE, 2017 The purinergic receptor P2X ligand-gated ion channel 3 (P2X3) is crucially involved in peripheral nociceptive processes of somatic and visceral pain. Endometriosis pain is considered as a kind of inflammatory and neuropathic pain.
Shaojie Ding +5 more
doaj +3 more sources
Dt-0111: a Novel P2x3 Receptor Antagonist [PDF]
Purinergic Signalling, 2022 Abstract Extracellular adenosine 5’-triphosphate (ATP) acts as an autocrine and paracrine agent, the actions of which on affected cells are mediated by P2 receptors (P2R). In the lungs and airways, ATP activates P2X3 and P2X2/3 receptors (R) localized on vagal sensory nerve terminals resulting in bronchoconstriction, and cough, and probably ...
Amir, Pelleg +3 more
openaire +3 more sources
Enhancement of P2X3 Receptor-Mediated Currents by Lysophosphatidic Acid in Rat Primary Sensory Neurons [PDF]
Frontiers in Pharmacology, 2022 Lysophosphatidic acid (LPA), a lipid metabolite, plays a role in both neuropathic and inflammatory pain through LPA1 receptors. P2X3 receptor has also been shown to participate in these pathological processes.
Wen-Long Qiao +12 more
doaj +2 more sources
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers [PDF]
Scientific Reports, 2021 ATP-dependent P2X3 receptors play a crucial role in the sensitization of nerve fibers and pathological pain pathways. They are also involved in pathways triggering cough and may contribute to the pathophysiology of endometriosis and overactive bladder ...
Adam J. Davenport +14 more
doaj +2 more sources
P2X3 receptor antagonism attenuates the progression of heart failure [PDF]
Nature Communications, 2023 AbstractDespite advances in the treatment of heart failure, prognosis is poor, mortality high and there remains no cure. Heart failure is associated with reduced cardiac pump function, autonomic dysregulation, systemic inflammation and sleep-disordered breathing; these morbidities are exacerbated by peripheral chemoreceptor dysfunction.
Renata M. Lataro +12 more
openaire +4 more sources
Population pharmacokinetic analysis of the
CPT: Pharmacometrics & Systems Pharmacology, 2023 AbstractGefapixant, a P2X3‐receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a population pharmacokinetic (PopPK) analysis that characterizes gefapixant pharmacokinetics (PKs), quantifies between‐ and within‐participant variability, and evaluates the impact of ...
Akshita Chawla +9 more
openaire +4 more sources
Comparative analysis of P2X1, P2X2, P2X3, and P2X4 receptor subunits in rat nodose ganglion neurons.
PLoS ONE, 2014 Nodose ganglion (NG) neurons are visceral primary sensory neurons. The transmission and regulation of visceral sensation is mediated mainly by the P2X purinoceptor (P2X receptor).
Lizhao Wang +4 more
doaj +2 more sources
Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study [PDF]
PharmaceuticalsBackground/Objectives: P2X3 receptor antagonists have been suggested as a potential treatment for urogenital, respiratory and pain conditions. This first-in-human (FiH) study evaluated filapixant, a new P2X3 receptor antagonist with high receptor ...
Klaus Francke +7 more
doaj +2 more sources
Structure of the human P2X3 receptor reveals the basis for subtype-selective inhibition by sivopixant. [PDF]
PLoS BiologyP2X receptors are ATP-gated cation channels, and the P2X3 subtype plays crucial roles in peripheral sensory neurons, including in chronic pain and chronic cough.
Zhixuan Zhao +10 more
doaj +2 more sources
Investigation on 2',3'-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists. [PDF]
ACS Med Chem Lett, 2019 Antagonists of the purinergic P2X3 receptors represent promising drugs for the treatment of inflammation and pain. The ATP derivative 2′,3′-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) has been described as a potent competitive inhibitor of this receptor.
Dal Ben D +9 more
europepmc +2 more sources